Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms LUCENT 2
  • Sponsors Eli Lilly

    • Most Recent Events

    • 05 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2018 Planned primary completion date changed from 30 Mar 2021 to 15 Jun 2021.
    • 17 Oct 2018 Planned initiation date changed from 3 Oct 2018 to 18 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top